<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176903</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-0916-PR-0032</org_study_id>
    <secondary_id>2010-018668-18</secondary_id>
    <nct_id>NCT01176903</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration</brief_title>
  <acronym>GLY2</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled, Cross-over Study to Investigate the Bronchodilator Efficacy and Safety After Single and Repeated Administrations of Different Doses of Glycopyrrolate Via pMDI in Moderate to Severe COPD Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and the efficacy of Glycopyrrolate as
      pMDI after single and repeated administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is divided into two parts:

      - Part 1 will be conducted according to a single-centre, randomized, double-blind,
      placebo-controlled, single-dose escalation, alternating crossover design in two groups of
      COPD patients.

      Treatments to be administered on Part 1 (SD1, SD2, SD3, SD4, SD5, SP). The primary objective
      of Part 1 is the evaluation of the safety and tolerability of Glyco after single
      administration.

      - Part 2 will be conducted according to a single-centre, randomized, double-blind,
      placebo-controlled, 4-period, 4-treatment, repeated dose cross-over design followed by an
      open-label extension period with tiotropium.

      Treatments administered on Part 2 (MD1, MD2, MD3, MP, Tiotropium). On the last treatment day
      in the morning, Formoterol 12 µg will be administered to all patients on top of placebo or
      Glyco or Tiotropium.

      The primary objective of Part 2 is the evaluation of the efficacy of Glyco after repeated
      administration.

      Part 2 will start after a safety review of the results obtained from Part 1.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to 24 hours after single administration</time_frame>
    <description>Adverse events, vital signs, ECG parameters, 24-hours ECG holter recording, clinical laboratory abnormalities.
This primary outcome is for the Part 1 of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung function (trough FEV1)</measure>
    <time_frame>12 hours post dose after repeated administration</time_frame>
    <description>This primary variable is for the Part 2 of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lung function</measure>
    <time_frame>up to 24 hours post dose</time_frame>
    <description>for Part 1 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function (other parameters)</measure>
    <time_frame>up to 12 hours after repated administration</time_frame>
    <description>for Part 2 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body plethysmography</measure>
    <time_frame>up tp 12 hours after repeated administration</time_frame>
    <description>for Part 2 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>up to 12 hours after single and repeated administration</time_frame>
    <description>Pharmacokinetics in plasma and urine. For Part 2 of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 12 hours after single and repeated administration</time_frame>
    <description>Adverse events, Vital signs, ECG parameters, 24-hour ECG holter recording. For Part 2 of the study.</description>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Glyco SD1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of Glyco pMDI dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco SD2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of Glyco pMDI dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco SD3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of Glyco pMDI dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco SD4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of Glyco pMDI dose level 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco SD5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of Glyco pMDI dose level 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single administration of Placebo pMDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco MD1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration of Glyco pMDI dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco MD2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration of Glyco pMDI dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glyco MD3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple administration of Glyco pMDI dose level 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple administration of placebo pMDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple administration of tiotropium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>pressurized metered dose inhaler</description>
    <arm_group_label>Glyco SD1</arm_group_label>
    <arm_group_label>Glyco SD2</arm_group_label>
    <arm_group_label>Glyco SD3</arm_group_label>
    <arm_group_label>Glyco SD4</arm_group_label>
    <arm_group_label>Glyco SD5</arm_group_label>
    <arm_group_label>Glyco MD1</arm_group_label>
    <arm_group_label>Glyco MD2</arm_group_label>
    <arm_group_label>Glyco MD3</arm_group_label>
    <other_name>CHF 5259</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <description>inhalation powder, hard capsule</description>
    <arm_group_label>Tiotropium</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>pressurized metered dose inhaler</description>
    <arm_group_label>Placebo SP</arm_group_label>
    <arm_group_label>Placebo MP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females patients aged 40-75 years;

          -  Written informed consent obtained;

          -  Diagnosis of moderate-severe COPD, according to the GOLD guidelines;

          -  Current or ex-smokers with a smoking history of ≥ 10 pack-years

          -  Post bronchodilator FEV1 between 40% and 80% predicted values (40% ≤ FEV1 &lt; 80%),
             documented at screening visit ;

          -  Post bronchodilator FEV1/Forced Vital Capacity (FEV1/FVC) ≤ 0.70 (absolute value)
             documented at screening visit;

          -  Airway reversibility of at least 100 mL within 30 to 45 minutes after inhalation of
             ipratropium 80µg.

        Exclusion Criteria:

          -  History of chronic or seasonal allergy

          -  Blood eosinophil count above 600 per µl

          -  Clinically relevant findings on physical examination laboratory and ECG parameters at
             screening

          -  Occurrence of clinically relevant abnormalities in the 24-h Holter ECG recording at
             screening;

          -  Significant disease not related to COPD (eg. Myocardial infarction, stroke within the
             preceding 6 months);

          -  Respiratory tract infection (including upper tract) 4 weeks prior to study entry
             requiring changing treatment;

          -  Patients requiring oxygen therapy on a daily basis for chronic hypoxemia;

          -  History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency, or any
             other significant lung disease which is considered to be clinically significant by the
             investigator.

          -  Intolerance/hypersensitivity or any contra-indication to treatment with M3 Antagonist
             or any of the excipients contained in the formulations used in the study.

          -  History of alcohol or substance abuse that in the opinion of the Investigator may be
             of clinical significance.

          -  Patients treated with slow-release oral or parental corticosteroids 8 weeks prior to
             Screening Visit.

          -  Patients treated with tiotropium in the 10 days prior to the Screening Visit;

          -  Pregnant or lactating women and female or male subjects not willing to use an
             acceptable method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dave Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicines Evaluation Unit Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-018668-18</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2010</study_first_submitted>
  <study_first_submitted_qc>August 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2010</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Glycopyrrolate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

